KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Prepaid Assets (2018 - 2025)

Historic Prepaid Assets for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $37.0 million.

  • Vir Biotechnology's Prepaid Assets fell 1422.54% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 1422.54%. This contributed to the annual value of $47.7 million for FY2024, which is 918.0% down from last year.
  • Vir Biotechnology's Prepaid Assets amounted to $37.0 million in Q3 2025, which was down 1422.54% from $41.5 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Prepaid Assets registered a high of $104.4 million during Q4 2022, and its lowest value of $26.5 million during Q1 2021.
  • Over the past 5 years, Vir Biotechnology's median Prepaid Assets value was $50.0 million (recorded in 2024), while the average stood at $55.5 million.
  • In the last 5 years, Vir Biotechnology's Prepaid Assets soared by 16535.93% in 2021 and then plummeted by 5249.49% in 2024.
  • Over the past 5 years, Vir Biotechnology's Prepaid Assets (Quarter) stood at $73.0 million in 2021, then skyrocketed by 42.95% to $104.4 million in 2022, then tumbled by 49.64% to $52.5 million in 2023, then fell by 9.18% to $47.7 million in 2024, then dropped by 22.56% to $37.0 million in 2025.
  • Its Prepaid Assets stands at $37.0 million for Q3 2025, versus $41.5 million for Q2 2025 and $42.4 million for Q1 2025.